SG10201907390PA - Improved photodynamic process and product obtained therefrom - Google Patents

Improved photodynamic process and product obtained therefrom

Info

Publication number
SG10201907390PA
SG10201907390PA SG10201907390PA SG10201907390PA SG 10201907390P A SG10201907390P A SG 10201907390PA SG 10201907390P A SG10201907390P A SG 10201907390PA SG 10201907390P A SG10201907390P A SG 10201907390PA
Authority
SG
Singapore
Prior art keywords
product obtained
obtained therefrom
photodynamic process
improved photodynamic
improved
Prior art date
Application number
Inventor
Jurjen Velthuis
Jong Liesbeth De
Manfred Rüdiger
Original Assignee
Kiadis Pharma Intellectual Property Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiadis Pharma Intellectual Property Bv filed Critical Kiadis Pharma Intellectual Property Bv
Publication of SG10201907390PA publication Critical patent/SG10201907390PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Abstract

IMPROVED PHOTODYNAMIC PROCESS AND PRODUCT OBTAINED THEREFROM The present invention relates to an improved photodynamic process in which micromolar or less of a photosensitive compound is used for photodynamic treatment. The product obtained is a mo re viable product which is more stable after freezing and thawing and shows im proved proliferating capacities. (No drawing to accompany the abstract)
SG10201907390P 2015-02-19 2016-02-19 Improved photodynamic process and product obtained therefrom SG10201907390PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15155755.0A EP3058957A1 (en) 2015-02-19 2015-02-19 Improved photodynamic process and product obtained therefrom

Publications (1)

Publication Number Publication Date
SG10201907390PA true SG10201907390PA (en) 2019-10-30

Family

ID=52477694

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201907390P SG10201907390PA (en) 2015-02-19 2016-02-19 Improved photodynamic process and product obtained therefrom
SG11201706007WA SG11201706007WA (en) 2015-02-19 2016-02-19 Improved photodynamic process and product obtained therefrom

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201706007WA SG11201706007WA (en) 2015-02-19 2016-02-19 Improved photodynamic process and product obtained therefrom

Country Status (13)

Country Link
US (1) US10577584B2 (en)
EP (2) EP3058957A1 (en)
JP (1) JP2018507205A (en)
KR (1) KR20170118822A (en)
CN (1) CN107206083A (en)
AU (1) AU2016221629A1 (en)
BR (1) BR112017017600A2 (en)
CA (1) CA2977202A1 (en)
IL (1) IL253919A0 (en)
MX (1) MX2017010527A (en)
RU (1) RU2017129576A (en)
SG (2) SG10201907390PA (en)
WO (1) WO2016131960A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3730627A1 (en) 2019-04-25 2020-10-28 Kiadis Pharma Intellectual Property BV Method for donor identity verification
EP3769770A1 (en) * 2019-07-23 2021-01-27 Kiadis Pharma Intellectual Property BV Method for inhibiting or preventing infection in a transplant recipient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556992A (en) 1994-09-02 1996-09-17 Universite De Montreal Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias
US5798523A (en) 1996-07-19 1998-08-25 Theratechnologies Inc. Irradiating apparatus using a scanning light source for photodynamic treatment
EP1005531A2 (en) * 1997-07-21 2000-06-07 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
US8409564B2 (en) * 1999-10-05 2013-04-02 Universite De Montreal Rhodamine derivatives for photodynamic diagnosis and treatment
ATE285793T1 (en) 1999-10-05 2005-01-15 Univ Montreal RHODAMINE DERIVATIVES FOR PHOTODYNAMIC DIAGNOSIS AND TREATMENT
EP1276734A1 (en) 2001-04-02 2003-01-22 Theratechnologies Inc. Halogenated rhodamine derivatives and applications thereof
EP1469733A4 (en) * 2001-11-29 2008-07-23 Therakos Inc Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
WO2006007515A2 (en) * 2004-07-01 2006-01-19 Board Of Regents, The University Of Texas System Functional assessment, specific enrichment and specific depletion of alloreactive human t cells
GB0420893D0 (en) * 2004-09-20 2004-10-20 Photopharmica Ltd Photosensitisers and their uses

Also Published As

Publication number Publication date
EP3058957A1 (en) 2016-08-24
US20180044630A1 (en) 2018-02-15
US10577584B2 (en) 2020-03-03
CN107206083A (en) 2017-09-26
WO2016131960A1 (en) 2016-08-25
MX2017010527A (en) 2018-01-16
RU2017129576A (en) 2019-03-21
RU2017129576A3 (en) 2019-07-17
BR112017017600A2 (en) 2018-05-08
JP2018507205A (en) 2018-03-15
AU2016221629A1 (en) 2017-09-07
IL253919A0 (en) 2017-10-31
EP3258968A1 (en) 2017-12-27
KR20170118822A (en) 2017-10-25
CA2977202A1 (en) 2016-08-25
SG11201706007WA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
MX2023007841A (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy.
MX2020003425A (en) Treatment of inflammatory disorders.
MX2020003702A (en) Cyclopropylamines as lsd1 inhibitors.
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
MX2019003623A (en) Compositions and methods for treating ophthalmic conditions.
EP3556858A3 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
MX2018009325A (en) Compounds and methods of treating rna-mediated diseases.
MX2017014430A (en) Transforming toy.
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
MA40457A (en) Drug combinations to treat multiple myeloma
GB2569488A (en) PD-1 specific aptamers
CL2018000009A1 (en) A process to treat milk
MX2020006283A (en) Process for the preparation of opicapone and intermediates thereof.
MX2019004182A (en) Process for the manufacture of 2,6-dimethyl-5-hepten-1-al.
IN2014MU00916A (en)
SG10201907390PA (en) Improved photodynamic process and product obtained therefrom
MX2016012758A (en) Hyperosmolar composition of hyaluronic acid.
MX2019006694A (en) Oxabicycloheptanes for modulation of immune response.
PH12017501944A1 (en) Method of making a mercury based compound, mercury based compound, methods of using the mercury based compound and uses of the mercury based compound
NZ721832A (en) Solid forms of tenofovir
PH12017501897A1 (en) 2-thiopyrimidinones
PH12017501872A1 (en) Methods of treating diseases
MX2020003416A (en) New treatment of sma.
MX2016010967A (en) New compositions for treating mechanical neuronal injuries.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis